StockNews.AI
KYTX
StockNews.AI
21 days

Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise

1. Kyverna will host a webcast on August 28, 2025, focusing on neuroimmunology. 2. KYV-101 targets myasthenia gravis and stiff person syndrome in its development. 3. The webcast includes presentations by leading KOLs and a Q&A session. 4. Kyverna's strategy emphasizes CAR T therapy and clinical trial milestones. 5. KYV-102 aims to expand patient reach with innovative manufacturing processes.

7m saved
Insight
Article

FAQ

Why Bullish?

The planned webcast highlights KYV-101's potential, positively influencing investor sentiment. Historical examples show that clear communication about drug potential often boosts stock prices, particularly before major trials.

How important is it?

The webcast aims to clarify the potential for KYV-101, addressing investor uncertainties, which can stabilize or increase stock price. The timing of the webcast aligns with upcoming clinical milestones, enhancing overall importance.

Why Long Term?

KYVERNA's clinical milestones and strategic communications can lead to increased investor attention over time. Past cases, such as CRISPR Therapeutics during trial announcements, show such strategies can yield long-term gains.

Related Companies

CRSPEDITALNY
Webcast to be held August 28, 2025, 11:00am ET , /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that the Company will host a webcast event with Key Opinion Leaders (KOLs) to discuss its neuroimmunology franchise. The event will take place on Thursday, August 28, 2025, from 11:00am to 1:30pm ET. Presentations will feature members of the Company's management team and the following renowned KOLs: Srikanth Muppidi, M.D., Stanford Medicine Ricardo Grieshaber-Bouyer, M.D., Ph.D., FAU Erlangen-Nümberg Aiden Haghikia, M.D., Hannover Medical School (MHH) The event will provide a deep dive into Kyverna's neuroimmunology franchise strategy, with a focus on KYV-101 and its potential in myasthenia gravis (MG) and stiff person syndrome (SPS), highlighting: The treatment landscape, patient experience and unmet need in MG and SPS KYV-101's differentiation and potential for durable drug-free, disease-free remission The details of our Phase 3 registrational trial in MG A high-level overview of Kyverna's focused commercial strategy, leading with neuroimmunology CAR T Multiple near-term value-creating milestones across the pipeline Following formal presentations, management will host a Q&A session. The event will be webcast live and those who intend to join can pre-register for the webcast here. The live webcast and supporting presentation materials will be available on the "Events & Presentations" section of Kyverna's Investor Relations webpage at ir.kyvernatx.com. An archived replay will also be available. About Kyverna Therapeutics   Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a clinical-stage biopharmaceutical company focused on liberating patients through the curative potential of cell therapy. Kyverna's lead CAR T-cell therapy candidate, KYV-101, is advancing through late-stage clinical development with registrational trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase 1/2 trials for patients with lupus nephritis.  The Company is also harnessing other KYSA trials and investigator-initiated trials, including in multiple sclerosis, to inform the next priority indications for the Company to advance into late-stage development.  Additionally, its pipeline includes next-generation CAR T-cell therapies in both autologous and allogeneic formats, including efficiently expanding into broader autoimmune indications and the potential to increase patient reach with KYV-102 using its proprietary whole blood rapid manufacturing process.  For more information, please visit https://kyvernatx.com. Forward-Looking Statements Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." The words, without limitation, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Forward-looking statements in this press release include, without limitation, those related to: Kyverna's upcoming virtual KOL event and the topics expected to be discussed at such event; the potential for KYV-101 to provide durable drug free, disease-free remission; Kyverna's commercial strategy and near-term value-creating milestones; the potential for KYV-102 to increase patient reach; and Kyverna's clinical trials, investigator initiated trials and named-patient activities. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties related to market conditions, the possibility that the FDA or other regulatory agencies may require additional trials or studies to support its intended BLA submission; intellectual property rights; and other factors discussed in the "Risk Factors" section of Kyverna's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that Kyverna has filed or may subsequently file with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this press release are based on the current expectations of Kyverna's management team and speak only as of the date hereof, and Kyverna specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Contact:  Investors: [email protected] Media: [email protected]  SOURCE Kyverna Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News